Addition of lomustine for bevacizumab-refractory recurrent glioblastoma

Acta Oncol. 2014 Oct;53(10):1436-40. doi: 10.3109/0284186X.2014.920960. Epub 2014 May 26.

Authors

Michaela Tonder¹, Günter Eisele, Tobias Weiss, Silvia Hofer, Katharina Seystahl, Antonios Valavanis, Roger Stupp, Michael Weller, Patrick Roth

Affiliation

¹ Department of Neurology, University Hospital Zurich , Zurich , Switzerland.

PMID: 24862539
DOI: 10.3109/0284186X.2014.920960

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Antibodies, Monoclonal, Humanized / administration & dosage*
Antineoplastic Agents / administration & dosage*
Antineoplastic Agents / adverse effects
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bevacizumab
Brain Neoplasms / drug therapy*
Disease Progression
Female
Glioblastoma / drug therapy*
Humans
Lomustine / administration & dosage*
Lomustine / adverse effects
Male
Middle Aged
Neoplasm Recurrence, Local / drug therapy*
Retrospective Studies

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Bevacizumab
Lomustine